Compare AbCellera Biologics Inc (ABCL) vs Nu Holdings Ltd (NU) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

NU stock trades at $13.61, showing no change in the last 24 hours. The technical outlook is bullish based on moving averages, with key support at $13 and resistance at $14. Fundamentally, the company demonstrates robust growth, with revenue increasing from $3.0B in 2022 to $10.63B in 2025 and net income turning positive to $2.87B. Recent earnings show mixed results, with a beat in Q3 2025 but misses in Q4 2025 and Q1 2026 against expectations.

The investment outlook is positive, supported by strong analyst consensus with a $14.98 price target and 55% buy ratings. Key opportunities include expansion in Latin America and a high return on equity of 30.04%. Risks involve recent earnings misses, competitive pressures, and macroeconomic volatility in emerging markets. The stock presents a growth opportunity but requires monitoring of execution and regional economic conditions.